Loading clinical trials...

Maintenance Transcranial Electrical Stimulation for Depression | Clinical Trials | Clareo Health

COMPLETEDNA

Maintenance Transcranial Electrical Stimulation for Depression

A Study of Transcranial Electrical Stimulation (TES) as a Maintenance Treatment for Depression

NCT01890356•The University of New South Wales

Summary

Transcranial electrical stimulation (TES) techniques offer a novel treatment approach for depression and have shown promising efficacy. However, there is no published data to date on their effectiveness as a maintenance treatment. This study will investigate ways of using TES as a maintenance treatment to prevent relapse in depression.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All participants will be ≥ 18 years old.
•Participants must have experienced a significant clinical response, defined as ≥ 50% decrease from baseline scores on the Montgomery Asberg Depression Rating Scale (MADRS).

Exclusion Criteria

•Inadequate response to acute trial of TES.
•Suicidality.
•Clinically defined neurological disorder or insult.
•Metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites.
•Pregnancy (women of childbearing age will be asked to undergo a urine pregnancy test prior to starting the study).
•Concurrent long acting benzodiazepines, ritalin or dexamphetamine medication.
•Treatment for depression is changed during months 3-9 of the trial.

Locations (1)

Black Dog Institute / University of New South Wales

Randwick, Sydney, New South Wales, Australia

Key Dates

Start Date

June 1, 2013

Primary Completion Date

February 1, 2018

Completion Date

February 1, 2018

Last Updated

March 27, 2018

Enrollment

ACTUAL participants

Conditions

Major Depressive DisorderBipolar Disorder

Interventions

Transcranial electrical stimulation

DEVICE

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 27, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Maintenance Transcranial Electrical Stimulation for Depression

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)